American Association for Cancer Research
Browse

Supplementary Figure S5 from Epigenetic and Oncogenic Inhibitors Cooperatively Drive Differentiation and Kill KRAS-Mutant Colorectal Cancers

Download (559.25 kB)
journal contribution
posted on 2024-12-02, 08:41 authored by Patrick Loi, Amy E. Schade, Carrie L. Rodriguez, Anjana Krishnan, Naiara Perurena, Van T.M. Nguyen, Yilin Xu, Marina Watanabe, Rachel A. Davis, Alycia Gardner, Natalie F. Pilla, Kaia Mattioli, Olesja Popow, Nuray Gunduz, Tamsin R.M. Lannagan, Samantha Fitzgerald, Ewa T. Sicinska, Jia-Ren Lin, William Tan, Lauren K. Brais, Kevin M. Haigis, Marios Giannakis, Kimmie Ng, Sandro Santagata, Kristian Helin, Owen J. Sansom, Karen Cichowski

Extended data related to Figure 5.

Funding

Cancer Research UK (CRUK)

Mark Foundation For Cancer Research (The Mark Foundation for Cancer Research)

National Cancer Institute (NCI)

United States Department of Health and Human Services

Find out more...

American Cancer Society (ACS)

History

ARTICLE ABSTRACT

Combined EZH2 and RAS pathway inhibitors kill KRAS-mutant colorectal cancer cells and promote durable tumor regression in vivo. These agents function by cooperatively suppressing the WNT pathway, driving differentiation, and epigenetically reprogramming cells to permit the induction of apoptotic signals, which then kill these more differentiated tumor cells.

Usage metrics

    Cancer Discovery

    Categories

    Keywords

    Cell SignalingGuanine nucleotide binding proteins and effectorsDrug MechanismsCellular responses to anticancer drugsDrug TargetsOncoprotein & tumor suppressor drug targetsGastrointestinal CancersColorectal cancerOncogenes & Tumor SuppressorsKras

    Licence

    CC BY

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC